Neumora Therapeutics, Inc. Common Stock (NMRA)
USD 10.18
(-6.3%)
USD 10.18
(-6.3%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -163.27 Million | -114.89 Million | -75.42 Million | -26.76 Million |
| Net Income | -235.92 Million | -130.9 Million | -237.31 Million | -99.27 Million |
| Depreciation & Amortization | 668 Thousand | 594 Thousand | 538 Thousand | 105 Thousand |
| Deferred income taxes | -3.74 Million | -1.28 Million | -53 Thousand | 3.08 Million |
| Stock-based compensation | 17.24 Million | 8.29 Million | 4.27 Million | 1.67 Million |
| Change in working capital | -8.89 Million | -6.94 Million | -961 Thousand | -3.12 Million |
| Other non-cash items | 67.37 Million | 15.34 Million | 158.09 Million | 70.77 Million |
| Investing Cash Flow | 64.38 Million | -168.01 Million | -817 Thousand | -11.23 Million |
| Investments in PPE | -117 Thousand | -511 Thousand | -817 Thousand | -1.3 Million |
| Acquisitions | - | - | - | - |
| Investment purchases | -109.07 Million | -226.36 Million | - | - |
| Sales/Maturities of investments | 178.16 Million | 71.86 Million | - | - |
| Other Investing Activities | -4.59 Million | -13 Million | - | -9.93 Million |
| Financing Cash Flow | 231.93 Million | 115.74 Million | 293.5 Million | 230.09 Million |
| Debt repayment | - | - | - | -55.9 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | -491 Thousand | - | - | -2000.00 |
| Common Stock Issuance | 233.37 Million | 115.74 Million | 960 Thousand | 3.19 Million |
| Other Financing Activities | -948 Thousand | 115.74 Million | 292.54 Million | 226.91 Million |
| Accounts receivables | - | - | - | - |
| Accounts payables | -581 Thousand | -1.24 Million | -759 Thousand | -4.67 Million |
| Inventory | - | - | - | - |
| Other working capital | -8.31 Million | -5.7 Million | -202 Thousand | 1.54 Million |
| Cash at beginning of period | 242.2 Million | 409.37 Million | 192.1 Million | - |
| Cash at end of period | 375.25 Million | 242.2 Million | 409.37 Million | 192.1 Million |
| Capital Expenditure | -117 Thousand | -511 Thousand | -817 Thousand | -1.3 Million |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | 133.04 Million | -167.16 Million | 217.27 Million | 192.1 Million |
| Free Cash Flow | -163.39 Million | -115.4 Million | -76.23 Million | -28.06 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -58.7 Million | -53.72 Million | -108.73 Million | -235.92 Million | -53.02 Million | -38.54 Million |
| Depreciation & Amortization | 160 Thousand | 158 Thousand | 166 Thousand | 668 Thousand | 173 Thousand | 171 Thousand |
| Deferred income taxes | - | - | -673 Thousand | -3.74 Million | -1.03 Million | - |
| Stock-based compensation | 12.76 Million | 7.37 Million | 6.05 Million | 17.24 Million | 6.45 Million | 2.54 Million |
| Change in working capital | -9.03 Million | 3.59 Million | -13.11 Million | -8.89 Million | -1.19 Million | 5.09 Million |
| Other non-cash items | 12.14 Million | 791 Thousand | 64.85 Million | 67.37 Million | 859 Thousand | 850 Thousand |
| Investing Cash Flow | 21.25 Million | -150 Million | 13.67 Million | 64.38 Million | 23.81 Million | 24.07 Million |
| Investments in PPE | - | -775 Thousand | -44 Thousand | -117 Thousand | -37 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -19.53 Million | -185.8 Million | -20.07 Million | -109.07 Million | -12.85 Million | -34.65 Million |
| Sales/Maturities of investments | 40.79 Million | 36.57 Million | 38.38 Million | 178.16 Million | 36.71 Million | 58.73 Million |
| Other Investing Activities | - | -775 Thousand | -4.59 Million | -4.59 Million | - | - |
| Financing Cash Flow | 2.65 Million | 1.84 Million | -481 Thousand | 231.93 Million | 232.02 Million | 292 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -491 Thousand | - | - |
| Common Stock Issuance | 2.65 Million | 1.84 Million | -481 Thousand | 233.37 Million | 232.02 Million | 292 Thousand |
| Other Financing Activities | 2.65 Million | 1.84 Million | -481 Thousand | -948 Thousand | 232.02 Million | -112 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -410 Thousand | 1.15 Million | -1.91 Million | -581 Thousand | 306 Thousand | 7.03 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -8.62 Million | 2.43 Million | -11.2 Million | -8.31 Million | -1.49 Million | -1.94 Million |
| Cash at beginning of period | 182.92 Million | 375.25 Million | 413.49 Million | 242.2 Million | 205.43 Million | 212.08 Million |
| Cash at end of period | 150.67 Million | 184.14 Million | 375.25 Million | 375.25 Million | 413.49 Million | 205.43 Million |
| Capital Expenditure | - | -775 Thousand | -44 Thousand | -117 Thousand | -37 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -32.24 Million | -191.11 Million | -38.24 Million | 133.04 Million | 208.06 Million | -6.65 Million |
| Free Cash Flow | -56.15 Million | -43.73 Million | -51.48 Million | -163.39 Million | -47.81 Million | -31.02 Million |
0IYS
300424
300792
000985
002104
SAFS